High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin’s lymphoma: Abstracted from: Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. Journal of Clinical Oncology 2003; 21: 2320–2325